205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.36%
Revenue growth above 1.5x ADI's 4.07%. David Dodd would confirm if the firm has a unique advantage driving sales higher.
8.36%
Gross profit growth above 1.5x ADI's 4.07%. David Dodd would confirm if the company's business model is superior in terms of production costs or pricing.
-371.30%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
-371.30%
Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.
37.50%
Net income growth of 37.50% while ADI is zero. Bruce Berkowitz would see if small gains can accelerate into a larger gap.
25.00%
EPS growth of 25.00% while ADI is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
25.00%
Diluted EPS growth of 25.00% while ADI is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
1.33%
Share change of 1.33% while ADI is at zero. Bruce Berkowitz would see if slight buybacks (or dilution) matter in the bigger picture.
1.33%
Diluted share change of 1.33% while ADI is zero. Bruce Berkowitz might see a minor difference that could widen over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
22.05%
Similar 10Y revenue/share CAGR to ADI's 23.34%. Walter Schloss might see both firms benefiting from the same long-term demand.
22.05%
5Y revenue/share CAGR similar to ADI's 23.34%. Walter Schloss might see both companies benefiting from the same mid-term trends.
22.05%
3Y revenue/share CAGR similar to ADI's 23.34%. Walter Schloss would assume both companies experience comparable short-term cycles.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
280.11%
10Y net income/share CAGR of 280.11% while ADI is zero. Bruce Berkowitz would see if minor gains can compound into a bigger lead over time.
280.11%
Net income/share CAGR of 280.11% while ADI is zero. Bruce Berkowitz would see if small mid-term gains can develop into a bigger lead.
280.11%
3Y net income/share CAGR of 280.11% while ADI is zero. Bruce Berkowitz sees if minor improvements can widen to a bigger advantage.
16.20%
10Y equity/share CAGR at 50-75% of ADI's 21.68%. Martin Whitman would note a lag in capital accumulation vs. the competitor.
16.20%
5Y equity/share CAGR at 50-75% of ADI's 21.68%. Martin Whitman would question a shortfall in capital accumulation vs. the competitor.
16.20%
3Y equity/share CAGR at 50-75% of ADI's 21.68%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
-46.00%
Cut dividends over 10 years while ADI stands at 0.00%. Joel Greenblatt suspects a weaker ability to return capital vs. the competitor.
-46.00%
Negative 5Y dividend/share CAGR while ADI stands at 0.00%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-46.00%
Negative near-term dividend growth while ADI invests at 0.00%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.